In 2024, Belgium leads with the highest per capita sales of anxiolytic medicine at $7.6, followed by Slovakia at $3.8. Norway and Slovenia report $2.6 and $2.5 respectively. Chile, Ireland, and Finland show more moderate sales at $2.1, $1.9, and $1.5, while Germany, New Zealand, and Costa Rica lag behind with $1, $0.3, and $0.2.
Year-on-year trends show varied dynamics: Slovakia and New Zealand saw significant increases of 7.89% and 8.45% respectively in 2023, while Belgium experienced no change. Slovenia and Finland had slight increases of 1.68% and 1.39%, whereas Germany and Chile faced declines of 1.89% and 0.93%. Costa Rica witnessed a considerable drop of 7.79%, with Ireland experiencing a decline of 3.75% in the same period.
The future trends to watch include the potential impacts of aging populations, increased mental health awareness, and economic factors influencing healthcare expenditure across countries. Emerging markets may display growth due to improving healthcare infrastructure and rising demand for mental health treatments.
Top countries in Anxiolytic Medicine Sales by Country
| # | 10 Countries | US Dollars PPP Per Capita | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Belgium | 7.6 | 2023 | 0% | 0% | View data |
| 2 | 2 Slovakia | 3.8 | 2023 | +2.7% | +7.89% | View data |
| 3 | 3 Norway | 2.6 | 2023 | +4% | +3.4% | View data |
| 4 | 4 Slovenia | 2.5 | 2023 | 0% | +1.68% | View data |
| 5 | 5 Chile | 2.1 | 2023 | +5% | -0.93% | View data |
| 6 | 6 Ireland | 1.9 | 2023 | -5% | -3.75% | View data |
| 7 | 7 Finland | 1.5 | 2023 | 0% | +1.39% | View data |
| 8 | 8 Germany | 1 | 2023 | 0% | -1.89% | View data |
| 9 | 9 New Zealand | 0.3 | 2023 | 0% | +8.45% | View data |
| 10 | 10 Costa Rica | 0.2 | 2023 | 0% | -7.79% | View data |
